CNS Drugs

, Volume 15, Issue 10, pp 755–764 | Cite as

Design of Clinical Trials of Antidepressants

Should a Placebo Control Ann be Included?
Current Opinion

Abstract

There is no doubt that available antidepressants are efficacious and effective. Nevertheless, more effective drugs with improved tolerability are needed.

With this need in mind, some protagonists claim that future antidepressants should be proved superior to, or at least as effective as, established antidepressants, making placebo control methodologically dispensable in clinical trials. Moreover, the use of placebo control is criticised as unethical because it might result in effective treatment being withheld.

There are, however, a number of methodological reasons why placebo control is indispensable for the proof of efficacy of antidepressants. Comparing investigational antidepressants only with standard antidepressants and not placebo yields ambiguous results that are difficult to interpret, be it in superiority or equivalence testing, and this method of assessment requires larger sample sizes than those required with the use of placebo control.

Experimental methodology not adhering to the optimal study design is ethically questionable. Restricting the testing of investigational antidepressants only to superiority over standard antidepressants is an obstacle to therapeutic progress in terms of tolerability and the detection of innovative mechanisms of action from which certain subgroups of future patients might benefit. The use of a methodology that requires larger samples for testing of superiority or equivalence is also ethically questionable.

In view of the high placebo response rates in trials of antidepressants, placebo treatment does not mean withholding effective treatment. Accepting the necessity of the clinical evaluation of new, potentially ineffective antidepressants implicitly means accepting placebo control as ethically justified. Three- or multi-arm comparisons including placebo and an active reference represent the optimal study design.

Keywords

Placebo Placebo Control Investigational Drug Last Observation Carry Forward Active Reference 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used in the preparation of this article, and the authors have no conflicts of interest that are relevant to its contents.

References

  1. 1.
    Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994; 331: 394–8PubMedCrossRefGoogle Scholar
  2. 2.
    Leber P. Challenges to the ethicality of clinical research. Psycho-pharmacol Bull 1996; 32: 11–3Google Scholar
  3. 3.
    Hellman S, Hellman DS. Of mice but not man: problems of the randomized clinical trial. N Engl J Med 1991; 324: 1585–9PubMedCrossRefGoogle Scholar
  4. 4.
    European Agency for the Evaluation of Medicinal Products. Guidance on choice of control group and related issues in clinical trials [topic E 10; CPMP/ICH/364/96]. The Fifth International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 2000 Nov 9–11; San DiegoGoogle Scholar
  5. 5.
    Leber P. Is there an alternative to the randomized controlled trial? Psychopharmacol Bull 1991; 27: 3–8PubMedGoogle Scholar
  6. 6.
    Klerman GL. Scientific and ethical considerations in the use of placebo controls in clinical psychopharmacology. Psychopharmacol Bull 1986; 22: 25–9PubMedGoogle Scholar
  7. 7.
    Leber P. The use of placebo control groups in the assessment of psychiatric drugs: an historical context. Biol Psychiatry 2000; 47: 699–706PubMedCrossRefGoogle Scholar
  8. 8.
    Rhodes AE, Lin E, Streiner DL. Confronting the confounders: the meaning, detection, and treatment of confounders in research. Can J Psychiatry 1999; 44: 175–9PubMedGoogle Scholar
  9. 9.
    Ferner U, Neumann N. Active control equivalence trials: some methodological aspects. Psychopharmacol 1992; 106 Suppl.: S93–5CrossRefGoogle Scholar
  10. 10.
    Davis JM, Janicak PG, Wang Z, et al. The efficacy of psycho-tropic drugs: implications forpower analysis. Psychopharmacol Bull 1992; 28: 151–6PubMedGoogle Scholar
  11. 11.
    Benkert O, Maier W. The necessity of placebo application in psychotropic drug trials. Pharmacopsychiatry 1990; 23: 203–5PubMedCrossRefGoogle Scholar
  12. 12.
    Prien RF. Methods and models for placebo use in pharmaco-therapeutic trials. Psychopharmacol Bull 1988; 24: 4–8PubMedGoogle Scholar
  13. 13.
    Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289–99CrossRefGoogle Scholar
  14. 14.
    Ravindran AV, Judge R, Hunter BN, et al. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatry 1997; 58: 112–8PubMedCrossRefGoogle Scholar
  15. 15.
    Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992; 7: 91–4PubMedGoogle Scholar
  16. 16.
    Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993; 13Suppl. 2: S18–22Google Scholar
  17. 17.
    Möller H-J, Berzewski H, Eckmann F, et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993; 26: 75–8PubMedCrossRefGoogle Scholar
  18. 18.
    Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735–9PubMedGoogle Scholar
  19. 19.
    Peselow ED, Sanfilipo MP, Difiglia C, et al. Melancholic/ endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 1992; 149: 1324–32PubMedGoogle Scholar
  20. 20.
    Heiligenstein JH, Tollefson GD, Faries DE. Response patterns of depressed outpatients with and without melancholia: a double blind, placebo controlled trial of fluoxetine versus placebo. J Affect Disord 1994; 30: 163–73PubMedCrossRefGoogle Scholar
  21. 21.
    Versiani M, Amin M, Chouinard G. Double blind, placebo controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28–34PubMedCrossRefGoogle Scholar
  22. 22.
    Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998; 13Suppl. 1: S29–39CrossRefGoogle Scholar
  23. 23.
    Bremner JD. Double blind comparison of mirtazapine, amitriptyline and placebo in major depression. Nervenheilkunde 1996; 15: 533–40Google Scholar
  24. 24.
    Marttila M, Jaaskelainen J, Jarvi R, et al. A double blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsycho-pharmacol 1995; 5: 441–6Google Scholar
  25. 25.
    Richou H, Ruimy P, Charbaut J, et al. A multicentre, double blind, clomipramine controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10: 263–71CrossRefGoogle Scholar
  26. 26.
    Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10Suppl. 2: S125–33CrossRefGoogle Scholar
  27. 27.
    Van Moffaert M, De Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10: 3–9PubMedCrossRefGoogle Scholar
  28. 28.
    Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656–63PubMedCrossRefGoogle Scholar
  29. 29.
    Cunningham LA. Once daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997; 9: 157–64PubMedGoogle Scholar
  30. 30.
    Thase ME. Efficacy and tolerability of once daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997; 58: 393–8PubMedCrossRefGoogle Scholar
  31. 31.
    Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61: 559–68PubMedCrossRefGoogle Scholar
  32. 32.
    Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51 Suppl. B: 18–27PubMedGoogle Scholar
  33. 33.
    Ekselius L, Von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997; 12: 323–31PubMedCrossRefGoogle Scholar
  34. 34.
    Bialik RJ, Ravindran AV, Bakish D, et al. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci 1995; 20: 265–70PubMedGoogle Scholar
  35. 35.
    Streiner DL. Placebo-controlled trials: when are they needed? Schizophren Res 1999; 35: 201–10CrossRefGoogle Scholar
  36. 36.
    Trindade E, Menon D. Selective serotonin reuptake inhibitors (SSRIs) for major depression Part 1. Evaluation of the clinical literature. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997Google Scholar
  37. 37.
    Temple RJ. When are clinical trials of a given agent versus placebo no longer appropriate or feasible? Control Clin Trials 1997; 18: 613–20PubMedCrossRefGoogle Scholar
  38. 38.
    Kienle GS, Kienle H. The powerful placebo effect: fact or fiction? J Clin Epidemiol 1997; 50: 1311–8PubMedCrossRefGoogle Scholar
  39. 39.
    Crow R, Gage H, Hampson S, et al. The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. The National Coordinating Centre for Health Technology Assessment. Health Technol Assess 1999; 3: 1–96Google Scholar
  40. 40.
    Delini-Stula A, Cameron A, Angst J. Comparative efficacy of antidepressants on anxiety features in depression: a meta-analysis of double-blind studies of imipramine and moclobemide against placebo. Int J Psychiatry Clin Pract 2000; 4: 111–7CrossRefGoogle Scholar
  41. 41.
    Nedopil N, Aldenhoff J, Amelung K, et al. Competence to give informed consent to clinical studies. Statement by the task force on ‘ethical and legal questions’ of the Association for Neuropsychopharmacology and Pharmacopsychiatry (‘Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatric (AGNP)’). Pharmacopsychiatry 1999; 32: 165–8Google Scholar
  42. 42.
    Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the food and drug administration database. Arch Gen Psychiatry 2000; 57: 311–7PubMedCrossRefGoogle Scholar
  43. 43.
    Montgomery SA. Long-term treatment of depression. Br J Psychiatry 1994; 165 Suppl. 26: 31–6Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of FrankfurtFrankfurt
  2. 2.Association of Private Health InsurersCologneGermany
  3. 3.Department of PsychiatryUniversity of MunichMunichGermany

Personalised recommendations